With 20 Planned Sites For the US Phase2
and the 10 in Europe, OCAT will be able to
quickly transition from FDA trials, to for
profit patient therapy.
And with the small number of Retina Specialists,
of around 2,000, they could potentially hold
regional seminars, provide transportation and
lodging, and reach each specialist directly.
Perhaps an East coast, West coast, and a Denver,
or Park City seminar, once or twice, and you reach
every Retinal Surgeon in the country, if not the entire
world!
If there are only 2,000 in the US, there can't be that
many more in Europe or Asia.
Going it alone, will in the long run, be a brilliant strategy.
And the long run is getting shorter and shorter.
Todays throw away comment about being well
received by the FDA, is something to ponder.
Remember, this is an Orphan disease, and
an unmet medical need. Safety has been proven,
phase 2 will prove it again and again, and resolve
the dosage and immuno suppression issues.
Also remember, nothing negative was announced today.
Some things are still in the works, but are as yet
unknown or unannounced. The unknown and the arbitrary
has always been a hobgoblin for the weak-minded,
and those prone to fear.
It has always been a research biotech, and remains
a risky bet. But it has never looked better.
